A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Directly including the variabil- Mathematical modeling as a tool to improve influenza vaccine production processes Stefanie Duvigneau * Robert Dürr * * , * * * Tanja Laske * * * Mandy Bachmann * * * Melanie ... This is in agreement with other model predictions, which determined the viral release as a kinetic bottleneck (Laske et al., 2018) . ...doi:10.1016/j.ifacol.2018.09.004 fatcat:2t7fcfbxyrd4jjhxpmyhdqbvem
OPEN ACCESS Citation: Rüdiger D, Kupke SY, Laske T, Zmora P, Reichl U (2019) Multiscale modeling of influenza A virus replication in cell cultures predicts infection dynamics for highly different infection ...doi:10.1371/journal.pcbi.1006819 fatcat:cxeoz7sfijanpowlpriqoxxe5m
For further details on generation and production of lentiviral vectors, and the transduction procedure the reader is referred to the Methods section of Laske et al. (2019) . ... For further technical details on cell culture maintenance, infection protocols as well as assaying procedures and data analysis the reader is referred to the Methods section in Laske et al. (2019)  ...doi:10.1371/journal.pcbi.1007810 pmid:32598363 fatcat:tr3duqel3bfzvkgxnh36vhsepq
Phenotypic variation in cultured mammalian cell lines is known to be induced by passaging and culture conditions. Yet, the effect these variations have on the production of viral vectors has been overlooked. In this work we evaluated the impact of using Madin–Darby canine kidney (MDCK) parental cells from American Type Culture Collection (ATCC) or European Collection of Authenticated Cell Cultures (ECACC) cell bank repositories in both adherent and suspension cultures for the production ofdoi:10.3390/ijms21176111 pmid:32854295 fatcat:pmvbcjasj5bkrozr4hn2q6ihai
more »... e adenoviral vectors type 2 (CAV-2). To further explore the differences between cells, we conducted whole-genome transcriptome analysis. ECACC's MDCK showed to be a less heterogeneous population, more difficult to adapt to suspension and serum-free culture conditions, but more permissive to CAV-2 replication progression, enabling higher yields. Transcriptome data indicated that this increased permissiveness is due to a general down-regulation of biological networks of innate immunity in ECACC cells, including apoptosis and death receptor signaling, Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling, toll-like receptors signaling and the canonical pathway of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling. These results show the impact of MDCK source on the outcome of viral-based production processes further elucidating transcriptome signatures underlying enhanced adenoviral replication. Following functional validation, the genes and networks identified herein can be targeted in future engineering approaches aiming at improving the production of CAV-2 gene therapy vectors.
., 2016a,b; Laske et al., 2016; Liao et al., 2016) . ... The impact of too high DIP to STV ratios and related self-interference is supported by a modeling study of our group (Laske et al., 2016) . ...doi:10.3389/fbioe.2019.00275 pmid:31681751 pmcid:PMC6813217 fatcat:kapeo7vy2ffnzce4s2nzheabue
Software: Tanja Laske. Supervision: Timo Frensing, Udo Reichl. Validation: Tanja Laske, Mandy Bachmann, Dagmar Wirth. Visualization: Tanja Laske. Writing -original draft: Tanja Laske. ... Writing -review & editing: Tanja Laske, Mandy Bachmann, Melanie Dostert, Alexander Karlas, Dagmar Wirth, Timo Frensing, Thomas F. Meyer, Hansjo ¨rg Hauser, Udo Reichl. ...doi:10.1371/journal.pcbi.1006944 fatcat:a5bgop6wqbfyre3t7vsoq4djlm
JAMA Network Open
Apathy is a frequent neuropsychiatric symptom in dementia of Alzheimer type and negatively affects the disease course and patients' and caregivers' quality of life. Effective treatment options are needed. To examine the efficacy and safety of the dopamine and noradrenaline reuptake inhibitor bupropion in the treatment of apathy in patients with dementia of Alzheimer type. This 12-week, multicenter, double-blind, placebo-controlled, randomized clinical trial was conducted in a psychiatric anddoi:10.1001/jamanetworkopen.2020.6027 pmid:32463470 pmcid:PMC7256670 fatcat:fqbso7dpdbaizfgy6dbbbtjc3i
more »... rological outpatient setting between July 2010 and July 2014 in Germany. Patients with mild-to-moderate dementia of Alzheimer type and clinically relevant apathy were included. Patients with additional clinically relevant depressed mood were excluded. Data analyses were performed between August 2018 and August 2019. Patients received either bupropion or placebo (150 mg for 4 weeks plus 300 mg for 8 weeks). In case of intolerability of 300 mg, patients continued to receive 150 mg throughout the study. Change on the Apathy Evaluation Scale-Clinician Version (AES-C) (score range, 18-72 points) between baseline and week 12 was the primary outcome parameter. Secondary outcome parameters included measures of neuropsychiatric symptoms, cognition, activities of daily living, and quality of life. Outcome measures were assessed at baseline and at 4, 8, and 12 weeks. A total of 108 patients (mean [SD] age, 74.8 [5.9] years; 67 men [62%]) were included in the intention-to-treat analysis, with 54 randomized to receive bupropion and 54 randomized to receive placebo. The baseline AES-C score was comparable between the bupropion group and the placebo group (mean [SD], 52.2 [8.7] vs 50.4 [8.2]). After controlling for the baseline AES-C score, site, and comedication with donepezil or galantamine, the mean change in the AES-C score between the bupropion and placebo groups was not statistically significant (mean change, 2.22; 95% CI, -0.47 to 4.91; P = .11). Results on secondary outcomes showed statistically significant differences between bupropion and placebo in terms of total neuropsychiatric symptoms (mean change, 5.52; 95% CI, 2.00 to 9.04; P = .003) and health-related quality of life (uncorrected for multiple comparisons; mean change, -1.66; 95% CI, -3.01 to -0.31; P = .02) with greater improvement in the placebo group. No statistically significant changes between groups were found for activities of daily living (mean change, -2.92; 95% CI, -5.89 to 0.06; P = .05) and cognition (mean change, -0.27; 95% CI, -3.26 to 2.73; P = .86). The numbers of adverse events (bupropion group, 39 patients [72.2%]; placebo group, 33 patients [61.1%]) and serious adverse events (bupropion group, 5 patients [9.3%]; placebo group, 2 patients [3.7%]) were comparable between groups. Although it is safe, bupropion was not superior to placebo for the treatment of apathy in patients with dementia of Alzheimer type in the absence of clinically relevant depressed mood. EU Clinical Trials Register Identifier: 2007-005352-17.
Lask Mcginnis Rousseau Tammen Raphael Michael | Detroit Bryan Gold Florida/Caribbean James E. Adam Taylor Lyons Roth Germany Hurbert Hubbes Angela Raguse-Foessel Hollywood Robert Mark Thomas K. ... Ingo Michael Nicole Jerzy Richard John Bruce Tim John lan Tanja Todd Ernest Michael Ryan Jason Patrick Elizabeth Marko Paul Richard Bailey Burton Diehl Doser Feinberg Gonzales Gorczyca Jastrow John Krell ...doi:10.5594/j16167 fatcat:hsdlkinrxna45p6qjluajt4xy4
International Pharmaceutical Abstracts
B. and Lask, A. Br. J. CLIN. PRACT. 32:169-171 (Jun) 1978 English A study utilizing naftidrofury! ... TANJA 16 0055 EFFECT OF CODEINE PHOSPHATE, LOMOTIL AND ISOGEL ON ILEOSTOMY FUNCTION Newton, C. R. (Res. Dept., St. ...
., 8544 Larsen, Povl, 9066 Larson, Mary Jo, 7324 Lask, Bryan, 7977 Laszlo, Janos, 7421 Lata, Jeff, 8321 Latimer, William W., 7050 latridis, Tilemachos, 7305 Laudy, Olav, 6365, 6366 Lauer, Kristen D., 8951 ... Linscheid, Thomas R., 8032 Linton, Jeremy M., 8666 Lipchik, Eve, 8285, 8286 Lippert-Gruener, M., 8147 Lippke, Sonia, 8445 Lippman, Louis G., 6390 Lipsitz, Joshua D., 7584 Lipusch, James T., 6959 Lischetzke, Tanja ...
., 3344 Lask, Bryan, 4715 Lasley Barajas, Heidi, 6150 Lassiter, G. ... ., 5593 Laudon, Moshe, 5623 Laukkala, Tanja, 5585 Laulhere, Tracy, 5606 Laungani, Rajesh, 4012 Laurent, Annie, 5600 Lauri, Eija-Riitta, 4105 Lauria, G. , 5280 Lauriello, John, 5586, 5904 Laver, Gary D, ...
., 35145 Koyama, Sachiko, 34110 Kral, Tanja V. E., 34113 Kramer, Arthur F., 33886 Kramer, Joel H., 35299 Kramer, John, 35043 Kramish Campbell, Marci, 35684 Krantz, Gunilla, 36013 Kranz, P. ... Jr., 34619 Larson, Joanne, 36054 Larson, Meredith, 36160 Larsson, Anne, 34017 Larsson, Kristina, 35754 Larue, Jaques, 33815 Lask, Bryan, 35948 Laso, Esteban, 33608 Latham, Jennifer, 33584 Lating, Jeffrey ...
Reduced BDNF blood levels have been reported in Alzheimer's disease (Laske et al., 2007) and mild cognitive impairment (Forlenza et al., 2010) . ... Thus, several studies indicate an increase of the BDNF levels and gene expression in patients with schizophrenia (Laske and Eschweiler, 2006) . ...doi:10.3389/fphys.2018.01337 pmid:30327610 pmcid:PMC6174219 fatcat:amkxz4zelvcuvk5glzbc5y7ejy
We thank Stefanie Lützner and Nancy Wynskersky for excellent technical support and Susanne Fritzsche and Tanja Laske for helpful discussions. ...doi:10.1099/jgv.0.000361 pmid:26647282 fatcat:5od7nvhkozf2nc7jbfphfahxyy
warunkach bilingwizmu polsko--niemieckiego jest długotrwałym procesem i nie kończy się po szóstym roku życia, jak to zwykle bywa u dzieci wychowanych w środowisku jednojęzycznym Z kolei niemiecka slawistka, Tanja ... XXII, z 3, s 31−50 Wójtowiczowa J , 1981, Wybór tekstów polonijnych z Zagłębia Ruhry, Warszawa Językoznawcze i glottodydaktyczne aspekty niepełnej polsko-niemieckiej dwujęzyczności, Nagórko A , 1996, Łask ...doi:10.12797/lv.11.2016.21.16 fatcat:s6pqw7xtdjdmlivtlo5paevzeu
« Previous Showing results 1 — 15 out of 81 results